Revvity

Phase A — Understand the business

Lens 1 · Company Overview

Revvity is the company that PerkinElmer became. In a three-step metamorphosis it (1) bought antibody/reagent leader BioLegend for ~$5.25B in 2021, (2) sold its Applied, Food & Enterprise Services businesses to New Mountain Capital for ~$2.45B in 2023, and (3) renamed the remaining Life Sciences + Diagnostics core Revvity on 2023-05-09. What's left is a focused life-science tools and diagnostics company headquartered in Waltham, MA, ~11,000 employees, selling in 160+ countries, an S&P 500 component listed as RVTY on the NYSE.

How it makes money — two segments:

• Life Sciences ($1,431.1M FY2025, 50% of revenue) — two lines: Life Sciences Solutions ($1,194.7M; reagents, antibodies, assays, instruments, imaging — the BioLegend/HTRF/AlphaLISA/Dharmacon portfolio) and Software ($236.4M; Signals ELN, ChemDraw, the Signals research/clinical SaaS stack).
• Diagnostics ($1,424.9M FY2025, 50% of revenue) — Immunodiagnostics ($869.9M; the EUROIMMUN autoimmune/allergy franchise) and Reproductive Health ($555.0M; newborn and prenatal screening — a genuine global #1).

The economic engine is razor/razorblade: instruments are placed (often free — the 10-K explicitly states the company "does not charge a fee for the use of the instrument and retains ownership of the placed instrument" and recognizes revenue on the reagent pull-through) and the recurring reagent/consumable stream is the profit. Product revenue is recognized at a point in time ($2,390.0M); service revenue ($466.1M) is recognized over time — and service has grown from $334.7M (FY2023) to $466.1M (FY2025), a deliberate recurring-mix shift.

Customers: pharma/biotech, CROs, academic and government labs, public-health authorities, hospitals, and (in newborn screening) national health systems. No single customer is >10% of revenue — concentration risk is end-market-level (pharma R&D budgets, NIH/academic funding, China diagnostics policy), not single-account.

customers.csv in the research layer is empty; the above is filing-grounded.

Lens 2 · Supply Chain

Upstream → Revvity → end customer, named:

• Inputs: specialty chemicals, fluorophores/dyes (the Brilliant Violet, StarBright, Spark/Fire dye families), antibodies and recombinant proteins (largely produced in-house post-BioLegend — a vertical-integration moat), oligonucleotides, radiochemicals (750+ radiochemicals for the Tri-Carb/MicroBeta scintillation line), microplates, plastics/consumables, and electronic/optical components for instruments. The 10-K flags that certain critical raw materials, key components and other goods are available only from "limited or single sources of supply," held under multi-year contracts with no minimum purchase requirements — a real but disclosed single-source risk.
• Manufacturing: Revvity runs its own global plants (Germany, UK, China, US among them — net long-lived assets: US $341M, Germany $131M, UK $41M, China $35M, other intl $201M). ~60% of business is conducted outside the US, providing a natural FX and tariff hedge on the cost side — though the tariff hit (below) shows the hedge is partial.
• Logistics: ships via UPS / FedEx (US), TNT / UPS / DHL (Europe), UPS (Asia) — named in the risk factors as concentration points.
• Downstream buyers: the pharma/biotech labs, CROs, academic/government institutions, and national newborn-screening programs above.

Chokepoints: (1) the single-source critical inputs; (2) tariff exposure on the Europe→US manufacturing lane — tariffs added $25M to FY2025 cost of revenue ($20M net gross-margin hit after mitigation), and $8M in Q1 FY2026 ($6M net), "primarily affecting products manufactured in Europe for the U.S. market". Note: the US Supreme Court ruled on 2026-02-20 that IEEPA does not authorize these tariffs; Revvity intends to seek refunds but has booked no refund receivable as of 2026-04-05 — a possible future tailwind, not yet in numbers.

supply-chain.md (kb/genomics) is missing; map is filing-derived.

Lens 3 · Competitive Advantages (moats)

Revvity's moat is real but narrow and bolted to two franchises, not the whole company:

1. Reagent/consumable razor-blade lock-in (Life Sciences Solutions + Immunodiagnostics). Once an instrument is placed and an assay is validated into a customer's regulated workflow, switching means re-validation — costly, slow, regulatory. BioLegend's catalog of 35,000+ antibody SKUs and the HTRF/AlphaLISA/DELFIA proprietary assay chemistries are genuine IP/process moats; you cannot trivially substitute a TotalSeq or Brilliant Violet conjugate.
2. Newborn screening (#1 globally) is a regulatory/installed-base fortress. National screening programs standardize on a vendor for years; Reproductive Health grew every year FY2023→FY2025 ($505M→$555M) through soft end-markets — the most defensive line in the company.
3. Software is the emerging moat / call option. Signals ELN + ChemDraw (a 40-year scientific-drawing standard) carry switching costs; the new SaaS push is growing fastest — Software revenue $178M → $201M → $236M (FY23→24→25), and management cites 40% ARR growth YoY and a Lilly "TuneLab" partnership as a launchpad for the Xynthetica AI platform.

Bargaining power: moderate. Over customers it is strong in locked-in reagent/screening franchises, weak in capital instruments (deferred/cancellable, the cyclical part). Over suppliers it is constrained by the single-source inputs. The moat does not show up in returns yet — ROIC ~3% (Lens 9/10) — because the price paid for the moat (BioLegend goodwill) sits as a $6.6B anchor on the balance sheet.

positioning.md / bottlenecks.md missing; grounded in filings + the call.

Lens 4 · Segments

All figures ``.

By segment — revenue & operating income (FY2025 vs FY2024):

By product line (FY2025 / FY2024 / FY2023):

• Life Sciences Solutions: $1,194.7M / $1,197.8M / $1,279.9M — declining (the cyclical reagent+instrument core, hit by the pharma/academic capex pullback).
• Software: $236.4M / $200.8M / $178.3M — the growth engine (+18% FY25).
• Immunodiagnostics: $869.9M / $828.6M / $787.4M — steady grower (EUROIMMUN).
• Reproductive Health: $555.0M / $527.8M / $505.0M — steady grower (newborn screening).

By geography (FY2025): US $1,126.3M (39%), China $425.1M (15%), Germany $177.7M, UK $126.8M, other international $1,000.2M. International is ~61% of revenue. China is the swing factor — $425M (15%) and falling ($454M→$450M→$425M FY23→24→25), the reason for the divestiture below.

The trend, decoded: both margins compressed in FY2025 (mix shift toward lower-margin lines + China policy + tariffs + FX). The structural story is decel in the cyclical Life Sciences Solutions razor-blade core, offset by steady Diagnostics annuities and fast-growing Software — i.e., the mix is slowly improving in quality even as headline growth stays low-single-digit.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print — fiscal Q1 FY2026, ended 2026-04-05)

The print:

• Revenue $711.1M, +7% YoY ($664.8M PY). But the quality is thin: +3% FX, +1% acquisitions → ~3% organic. The quarter also carried an extra (53rd) fiscal week, flattering the comp.
• GAAP operating income $75.9M (vs $72.2M); GAAP net income $40.7M, diluted EPS $0.36 (vs $0.35).
• Adjusted EPS $1.06 vs $1.01 PY — and above the $1.02–$1.04 implied outlook. The chasm between $0.36 GAAP and $1.06 adjusted is the whole RVTY story: amortization of acquired intangibles was ~$85M in the quarter ($35.0M in COGS + $50.1M in SG&A).
• Segments: Life Sciences $361.8M (+6%, but −240bps seg margin), Diagnostics $349.3M (+8%, Reproductive Health +$20.6M leading).
• Gross margin compressed 200bps to 54.5% (from 56.5%) — mix, FX, tariffs, the extra week.
• Adjusted operating margin 23.6%, above the 23% outlook.

Guidance — recut around the China divestiture: FY2026 pro-forma revenue $2.81–2.84B, pro-forma organic growth 3–4%, pro-forma adjusted EPS $5.20–5.30.

Balance-sheet flags:

• Cash $860.3M (down from $919.9M at YE) — drained by buybacks + the ACD/Labs acquisition.
• Receivables jumped to $744.7M at YE2025 from $632.4M (+18% on +4% revenue) — China collection timing per MD&A; worth watching as a quality flag.
• The €500M 1.875% 2026 Notes (~$589M) moved to current — a near-term refi (July 2026), to be repaid from cash or the $1.5B revolver.
• Operating cash flow $125.9M in Q1 (vs $134.1M PY), down on working-capital timing.

Market reaction: shares rose on the beat despite the soft organic line — the Street rewarded the margin beat + the China-exit "self-help" narrative over the low growth.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the research-layer shelf (transcripts/ empty); this lens is ``, primarily the Q1-FY2026 call (2026-05-05).

What management is focused on (Q1 FY2026):

• "Self-help" margins over growth. The dominant message: sharpen the portfolio (exit China IDX), expand adjusted margin, lean on buybacks — because the end-market won't do the heavy lifting.
• A tentatively-improving biopharma signal. Life Science Solutions was "up low single-digit from pharma/biotech in Q1 — the strongest core growth from this customer group since Q2 2023." The framing — "slowly moving in the right direction… more important than the level itself" — is a CEO managing expectations toward an eventual normalization, not declaring one.
• Software as the headline growth story. "Customer engagement remains high," the Lilly TuneLab partnership as a launchpad for Xynthetica, "strong double-digit" APV, 40% ARR growth YoY.
• China candor. Singh's language — "persistent policy-induced headwinds" in China diagnostics on demand and pricing; staying would require heavy localization investment — is unusually direct, and frames the divestiture as a value-accretive subtraction.

Tone shift over time (inferred): the multi-year arc has moved from post-rebrand growth optimism (2023) → "trough is near, end-markets bottoming" (2024–25) → "we'll manufacture the earnings via mix, margins and buybacks while we wait" (2025–26). That is a realistic, slightly defensive tone — appropriate, but not the language of a company that sees a demand inflection imminent. (Lower confidence — transcript not on shelf; pull Fool/Insider-Monkey transcripts on next refresh to grade the 4-call sentiment delta properly.)

Lens 7 · Comps

Peer multiples are `` with source/date or n/a. Never fabricated. RVTY's own multiples and peers gathered June 2026.

Read: On forward P/E (~16.4x), RVTY is the cheapest of the diversified-tools complex — a clear discount to TMO (~26x), Agilent (~25x) and the DHR/Bio-Rad premium names; only Bruker sits near it on EV/EBITDA (13.9x vs 14.6x). The discount is earned, not free: it reflects ~3% organic growth, the lowest GAAP returns in the group (3.3% ROE), the China overhang, and the perception that Revvity is the "show-me, self-help" name of the cohort. The bull framing is mean-reversion toward peer multiples if organic growth re-accelerates and margins inflect; the bear framing is that a low-growth tools compounder should trade at a discount to TMO/DHR.

Caveat: the trailing P/E of 47x is not meaningful — GAAP EPS is suppressed by ~$340M/yr of acquired-intangible amortization. Forward P/E and EV/EBITDA are the honest lenses here.

Lens 8 · Stock-Price Catalysts (>5% moves, last ~5 years)

`` + the 10-K's own 5-year total-return table.

The five-year tape is brutal and is the central fact of this name. Revvity's cumulative total return (dividends reinvested), indexed to 100 on 2021-01-03:

A holder from Jan-2021 to Dec-2025 lost ~32% total return while the S&P nearly doubled (+96%) and even the tools index was roughly flat. RVTY underperformed not just the market but its own sector.

What moves the stock (pattern):

1. The 2021 COVID/PCR peak and its unwind — the single biggest move. RVTY rode COVID diagnostics to 140 by end-2021, then gave it all back as the COVID tailwind reversed and the BioLegend-era multiple de-rated. This is the dominant 5-year driver.
2. The post-COVID biopharma/academic capex recession (2022–2024) — sustained de-rating as instrument demand froze. The stock hit a 52-week high of $129.50 on 2024-11-06 and has since fallen ~17%.
3. Quarterly organic-growth prints vs the ~3–4% bar and guidance revisions — the swing factor now. Q3 2025 was a negative shock (GAAP EPS $0.41 vs $0.76 PY, net income −49%); the Q1 2026 beat (+margins, China exit) was a positive one.
4. The China divestiture announcement — a structural, sentiment-resetting catalyst.

The lesson: the market reacts to organic-growth surprises and margin/guidance revisions against a low bar, and to China/policy headlines — not to the GAAP headline (which everyone discounts for amortization). This is a "show me the organic acceleration" stock.

---

Phase C — Judge people & books

Lens 9 · Management

CEO Prahlad Singh (61) — President & CEO since 2020; joined PerkinElmer in 2014 running Diagnostics; ex-GE Healthcare, Philips Healthcare, Bristol-Myers Squibb Medical Imaging; PhD chemistry (Missouri), MBA (Northeastern). The entire senior team is a GE alumni cluster — CFO Maxwell Krakowiak (36, ex-GE Corporate Audit), CAO Anita Gonzales (ex-GE Aviation controller), Global Ops EVP Tajinder Vohra (ex-GE Healthcare, Six-Sigma Black Belt). This is a textbook GE-operating-system management team: disciplined, process/margin-oriented, M&A-and-portfolio-surgery fluent — exactly the team you'd want for a "self-help, manufacture-the-margin, prune-the-portfolio" chapter, and arguably not the team that organically invents a growth inflection.

1. Track record — the transformation is the resume. Singh's team executed the PerkinElmer→Revvity pivot: the $5.25B BioLegend buy (2021) and the $2.45B sale of Applied/Food/Enterprise to New Mountain (2023). Strategically coherent (concentrate on higher-growth, higher-margin LS+Dx). Financially, the jury is hostile: the stock is down ~32% total return over five years (Lens 8), and the assets bought at peak multiples now earn ~3% ROIC.
2. Tenure & skin in the game — thin and net-selling. Singh holds ~113K shares directly (+~47K via family trust) — almost entirely RSU-vesting-derived, ~$12M of stock against an $11B company. Over the trailing 6 months to May-2026: 0 purchases, 5 sales (~25,525 shares, ~$2.56M); he has also gifted shares to a children's trust. No open-market buying through the multi-year decline — the classic professional-manager signature, not an owner-operator backing up the truck at $105.
3. Capital-allocation history — buyback-forward, returns-light. FY2025: $820.8M of buybacks (+122% YoY), $215.8M R&D (+10%), $32.8M dividends, and a fresh $1.0B repurchase authorization (Oct-2025). Share count fell from 120.6M to 112.3M in one year — genuine per-share accretion. But buying back stock while ROIC sits ~3% is the tell: management implicitly judges its own shares the best available return — a fair read at 16x forward, but also an admission that organic reinvestment opportunities aren't clearing the bar.
4. Red flags — light. Comp is not egregiously called out; no related-party deals surfaced. The honest red flag is value creation, not governance: a five-year transformation that destroyed relative shareholder value, and goodwill ($6.6B) that has not yet been impaired but whose Life Sciences Solutions reporting unit (carrying $4.5B goodwill) cleared its FY2025 impairment test by only 10–20% — the auditor's sole Critical Audit Matter. That cushion is thin.
5. Archetype — professional managers / portfolio surgeons. Implication: expect more divestitures, bolt-on software/reagent M&A (ACD/Labs, $72M, closed Q1-2026), relentless margin work, and aggressive buybacks — and do not underwrite a self-generated organic-growth renaissance. The upside is a re-rating delivered by discipline + an end-market recovery they don't control.

Lens 10 · Forensic Red Flags

Forensic lens. Every figure labeled.

Income statement:

• The GAAP-vs-adjusted gap is structural, not abusive — but large. FY2025 GAAP operating income $356.6M vs adjusted segment OI $802.4M; the bridge is ~$340M of acquired-intangible amortization plus restructuring ($55.9M), litigation ($12.2M), transformation ($9.3M). The amortization is non-cash and economically defensible to add back; the recurring restructuring (a charge every year: $26.6M FY23, $17.5M FY24, $55.9M FY25) is the item to police — "non-recurring" charges that recur are an adjusted-EPS flatterer. FY2025 restructuring hit ~5% of the workforce.
• SBC: present but not flagged as outsized; the BioLegend post-acquisition SBC tail has rolled off (was $0.6M COGS/$2.2M R&D in FY2024, gone in FY2025).

Balance sheet:

• $8.9B of goodwill + intangibles on $12.2B total assets (73%). Goodwill alone is $6.6B; equity is $7.25B — i.e., tangible book is deeply negative. The Life Sciences Solutions reporting unit ($4.5B goodwill) passed impairment by only 10–20% in Nov-2025 — a genuine, auditor-flagged impairment risk if revenue growth or the discount rate moves against them. This is the single biggest accounting risk.
• Receivables outran revenue: AR +18% ($632.4M→$744.7M) on +4% revenue YoY, attributed to China collection timing — monitor for a future write-down or DSO creep.
• Debt ~$3.2B ($588.8M current + $2,631.2M LT), with the €500M 2026 Notes now current (July-2026 refi). Net debt ~$2.3–2.4B; investment-grade, with a maturity ladder (2026/2028/2029/2031×2/2051 Notes) — manageable, but a ratings downgrade would raise costs and tighten covenants.

Cash flow:

• Cash conversion is decent and the adjustments are mostly real. FY2025 operating cash flow from continuing ops $589.0M (down from $665.0M) against $239.9M income — the gap is D&A ($405.3M). FCF (OCF − capex $73.5M) ≈ $515M. Capex is light (~2.6% of revenue), characteristic of a reagent/software model. Cash earnings are healthy even though GAAP earnings look thin — the inverse of an aggressive-accounting flag.

Regulatory findings (required sub-section):

• SEC EDGAR EFTS (LR + AAER): No Litigation Releases and no AAERs naming Revvity in the 2021-06-29 → 2026-06-29 window. Clean on SEC accounting/fraud enforcement.
• Non-SEC enforcement (web): No FDA / DOJ / FTC / SEC enforcement actions or consent decrees surfaced for Revvity or PerkinElmer in 2024–2026. BUT one material civil matter: more than two dozen cannabis-testing laboratories are suing Revvity Health Sciences (ex-PerkinElmer) for a collective ~$1B (a $286M consolidated suit refiled in Suffolk County, MA, July 2025), alleging Revvity "knowingly and intentionally" marketed and sold lab instruments as compliant with state cannabis-testing requirements while internal emails allegedly conceded the equipment "could not – and w(as) not designed to" perform the analyses. This is a fraud-flavored product-liability claim, not yet adjudicated; it dovetails with the 10-K's own "significant litigation matters and settlements" line ($12.2M FY2025; $10.6M in Q1-2025 alone). Material to monitor — quantify on next refresh.
• 10-K Item 3 (Legal Proceedings): ordinary-course claims with established accruals; the company also carries environmental PRP/Superfund exposure at current/former sites (legacy of the industrial PerkinElmer) with accruals it deems probable and estimable.
• Net: clean on SEC/accounting enforcement; the live risk is the ~$1B cannabis-lab fraud suit + the thin-cushion goodwill + the recurring "non-recurring" restructuring.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (next three fiscal years: FY2026 / FY2027 / FY2028)

Built bottom-up from FY2025 actuals + the company's FY2026 pro-forma guide. All outputs with arithmetic; consensus shown as a cross-check. No forecast.ts create — --watchlist rules.

Anchors:

• FY2025 adjusted EPS ≈ $4.90 — flagged: I could not source the exact FY2025 full-year adjusted EPS figure from the on-disk filings (the 10-K reports GAAP $2.07; adjusted is a non-GAAP press-release metric not in the 10-Q either). Treat the $4.90 as a derived anchor, n/a — not directly sourced.
• Company FY2026 guide: pro-forma adjusted EPS $5.20–5.30, pro-forma organic 3–4%.

Base case (organic 3–4%, ~flat-to-slightly-up adj. margin, ~3% annual share-count reduction from the $1B buyback, China IDX divested mid-cycle):

• FY2026 adj. EPS ≈ $5.25.
• FY2027 adj. EPS ≈ $5.85 — vs consensus ~$6.01.
• FY2028 adj. EPS ≈ $6.45.

Bull case (organic re-accelerates to mid-single-digits as biopharma normalizes + software scales to a visible mix-shift, margin +100–150bps, buyback continues):

• FY2026 ~$5.35 → FY2027 ~$6.30 → FY2028 ~$7.20.

Bear case (organic stalls ~0–2% on a stalled biopharma recovery + worse China/policy, margin flat-to-down on tariffs/mix, goodwill impairment risk on Life Sciences Solutions):

• FY2026 ~$5.10 → FY2027 ~$5.30 → FY2028 ~$5.55.

The honest summary: this is a high-single-to-low-double-digit EPS compounder whose growth is ~⅓ organic, ~⅓ margin, ~⅓ buyback — durable but unexciting, and entirely dependent on (a) an end-market recovery management doesn't control and (b) avoiding a goodwill write-down. Consensus FY26 ~$5.40 / FY27 ~$6.01 sits at/above my base — the Street is underwriting the recovery I'd haircut.

Lens 12 · Bull vs Bear

Bull case. Revvity is a collection of genuinely good razor/razorblade and screening franchises trading at a trough multiple (~16x forward, ~14.6x EV/EBITDA) and a trough sentiment. Three levers can re-rate it: (1) biopharma/academic demand normalizes — Q1 2026 already showed "the strongest core pharma/biotech growth since Q2 2023," the first green shoot in two years; (2) Software compounds into a mix-shifter — 40% ARR growth, the Lilly/Xynthetica AI partnership, a structurally higher-multiple revenue stream growing inside a hardware-multiple company; (3) self-help delivers — China IDX exit lifts pro-forma growth and margin, the $1B buyback shrinks the count ~3%/yr, and the IEEPA tariff refund is an un-modeled call option. If organic re-accelerates to mid-single-digits and the multiple drifts toward Agilent/TMO (~20–25x), the stock has 30–50% upside — and the consensus ~$113–121 PT already prices ~7–15% of that.

Bear case (2–3 permanent-impairment-grade risks). (1) The growth was always cyclical, and "normal" is ~3%, not the 7–8% of the COVID/BioLegend era — in which case a low-growth tools roll-up deserves a discount to TMO/DHR, and there is no re-rating, just a value trap. (2) Goodwill impairment. Life Sciences Solutions ($4.5B goodwill) cleared its test by only 10–20%; a continued LSS revenue decline or a higher discount rate triggers a multi-billion write-down that, while non-cash, shatters the "compounder" narrative and the management credibility behind the BioLegend deal. (3) China + policy + tariffs are structural, not transitory — 15% of revenue in secular decline, US/NIH funding uncertainty pressuring academic demand, and a Europe→US tariff lane that the IEEPA reprieve may not durably fix.

Pre-mortem (it's Dec-2027 and the thesis broke): biopharma never re-accelerated past low-single-digits, the academic/NIH funding cuts bit harder than feared, Life Sciences Solutions revenue kept sliding and forced a goodwill impairment that re-anchored the bear case, the cannabis-lab suit produced a nine-figure settlement, and the buyback — funded partly off the revolver as the 2026 Notes were refinanced — looked like financial engineering papering over a no-growth core. The multiple compressed toward Bruker, not toward TMO.

Are multiples too high? No — RVTY is the cheapest of the diversified-tools cohort on forward earnings. The question is whether they're too low (re-rating thesis) or correctly low (value-trap thesis). That hinges entirely on organic growth re-accelerating.

Contrarian view (what the market refuses to see): the bears extrapolate ~3% organic forever and treat the GAAP 47x / 3% ROIC as the truth. What they under-weight: the Software line is quietly becoming a different, better business (40% ARR growth, AI/pharma partnerships) inside a company the market still prices as a cyclical instrument vendor — and a GE-bred management team is exactly the kind to keep grinding margin + buying back stock at a trough until the mix-shift and the cycle do the re-rating for them. The variant view is "boring quality, mispriced as broken." But it requires patience and an end-market you must independently believe is bottoming.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• What structurally breaks the model? A permanent reset of pharma/academic R&D intensity (post-COVID normalization that overshoots below trend; sustained NIH/government funding cuts) would freeze the cyclical Life Sciences Solutions razor-blade core — already in decline ($1,280M→$1,198M→$1,195M FY23→24→25), not just deceleration. The "recovery" is a hope, not a trend.
• Where is revenue concentrated, and what shifts it? China (15%, $425M and falling) and the cyclical reagent/instrument core (~42% of revenue in Life Sciences Solutions). China is being amputated (divestiture) because management can't win there — a tacit admission of structural, not transitory, weakness. The Diagnostics annuities are good but only ~half the company.
• Why is the moat weaker than bulls think? In capital instruments there's no moat — purchases are deferrable and cancellable, which is why the cycle hammered the stock. The reagent lock-in is real but doesn't generate pricing power sufficient to offset volume — gross margin fell 104bps (FY25) and 200bps (Q1-26) despite the "sticky" portfolio. A moat that can't defend margin in a downturn is a weak moat.
• Most dangerous competitor bulls underestimate? Danaher and Thermo Fisher — scale buyers who can out-invest, out-bundle (full-workflow + service), and out-acquire Revvity, and Bruker/Bio-Techne/Sartorius/10x in the reagent/antibody and spatial-bio niches. In Software, the entrenched ELN/informatics incumbents (Benchling, Dotmatics) contest the Signals stack. Revvity is sub-scale ($2.86B) versus TMO ($43B) / DHR ($24B+).
• Worst capital-allocation moves? Paying $5.25B for BioLegend at a 2021 peak multiple, now earning ~3% ROIC and sitting as $4.5B of thin-cushion goodwill — value destruction dressed as transformation. And $820M of buybacks in FY2025 while ROIC is ~3% — accretive to EPS, but a tell that management can't find better internal returns.
• What must hold for $105? Forward EPS of ~$5.25 growing ~10%/yr and the 16x forward multiple holding and no goodwill impairment and the cannabis suit not producing a nine-figure hit. If organic disappoints by 20–30% (say ~0–1% instead of 3–4%), FY2027 EPS lands nearer $5.30 than $6.00 and the multiple compresses toward Bruker (~13–14x), implying a stock in the $70–80s — i.e., back toward the 5-year-trough total-return reality of Lens 8.
• The single scenario that permanently impairs: a Life Sciences Solutions goodwill impairment ($4.5B at risk, 10–20% cushion) triggered by continued LSS revenue decline. Plausible — not base-case, but a live tail given the auditor flagged it as the sole Critical Audit Matter.

Lens 14 · Management Questions (ordered by information value)

1. Life Sciences Solutions revenue has now declined three straight years ($1,280M→$1,198M→$1,195M). What is the organic trajectory ex-FX/ex-acquisitions, and what specifically inflects it back to growth rather than just stabilizing?
2. The Life Sciences Solutions reporting unit cleared its goodwill test by only 10–20%. What revenue-growth and discount-rate assumptions underpin that fair value, and at what organic-growth rate does it impair?
3. You're buying back stock aggressively at a ~3% ROIC. Why is repurchase the best use of capital versus deleveraging or higher-return reinvestment — and what ROIC do you target by 2028?
4. Software is growing 40% ARR. What is Software's current revenue run-rate, gross margin, and net retention — and what does the company look like at the mix where Software is 15–20% of revenue?
5. On the cannabis-testing-lab litigation (~$1B claimed): what is your range of reasonably-possible loss, your reserve, and your read on the internal communications cited in the complaint?
6. China is ~15% of revenue and you're divesting Immunodiagnostics there. What is the remaining China exposure post-divestiture, and is the rest defensible or also at policy risk?
7. "Non-recurring" restructuring has recurred every year and rose to $55.9M in FY2025. When does it actually end, and what's the steady-state adjusted-to-GAAP bridge you want investors to underwrite?
8. The IEEPA tariff ruling could yield refunds you haven't booked. Quantify the potential refund and the run-rate tariff exposure if the reprieve doesn't hold.
9. Pharma/biotech demand was "the best since Q2 2023." Is that a durable inflection or a comp/destocking artifact — and what's your visibility into 2H 2026 biopharma capex?
10. AR rose 18% on 4% revenue (China collection timing). When does DSO normalize, and is any of that balance at write-down risk?
11. The €500M 2026 Notes refinance in July. What's the expected rate, and how does it change interest expense and the buyback's funding mix?
12. After ACD/Labs and the China exit, what does the M&A pipeline look like — more software bolt-ons, or larger reagent/diagnostics assets?
13. Reproductive Health is a global #1 growing through soft markets. What's the long-term growth ceiling, and what defends it from lower-cost NGS-based screening entrants?
14. Adjusted operating margin was 23.6% in Q1. What's the realistic path to a higher-20s% margin, and how much is mix vs cost-out?
15. You came up through GE's operating system. What's the single metric (not EPS) by which you want shareholders to judge whether this management has created value over the next three years?

---